173 related articles for article (PubMed ID: 37409348)
1. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Burger PM; Dorresteijn JAN; Fiolet ATL; Koudstaal S; Eikelboom JW; Nidorf SM; Thompson PL; Cornel JH; Budgeon CA; Westendorp ICD; Beelen DPW; Martens FMAC; Steg PG; Asselbergs FW; Cramer MJ; Teraa M; Bhatt DL; Visseren FLJ; Mosterd A; ; ;
Eur J Prev Cardiol; 2023 Dec; 30(18):1950-1962. PubMed ID: 37409348
[TBL] [Abstract][Full Text] [Related]
2. Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease.
Holtrop J; Bhatt DL; Ray KK; Mach F; Smulders YM; Carballo D; Steg PG; Visseren FLJ; Dorresteijn JAN
Eur J Prev Cardiol; 2024 Apr; 31(6):754-762. PubMed ID: 38324720
[TBL] [Abstract][Full Text] [Related]
3. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
4. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
[TBL] [Abstract][Full Text] [Related]
5. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
Kaasenbrood L; Ray KK; Boekholdt SM; Smulders YM; LaRosa JC; Kastelein JJP; van der Graaf Y; Dorresteijn JAN; Visseren FLJ
Heart; 2018 Oct; 104(20):1699-1705. PubMed ID: 29622600
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
Nelson K; Fuster V; Ridker PM
J Am Coll Cardiol; 2023 Aug; 82(7):648-660. PubMed ID: 37558377
[TBL] [Abstract][Full Text] [Related]
7. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Kones R
Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
[TBL] [Abstract][Full Text] [Related]
8. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.
Stam-Slob MC; van der Graaf Y; Greving JP; Dorresteijn JA; Visseren FL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214794
[TBL] [Abstract][Full Text] [Related]
11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
12. Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment.
Gynnild MN; Hageman SHJ; Spigset O; Lydersen S; Saltvedt I; Dorresteijn JAN; Visseren FLJ; Ellekjær H
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35459718
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.
Fiolet ATL; Opstal TSJ; Mosterd A; Eikelboom JW; Jolly SS; Keech AC; Kelly P; Tong DC; Layland J; Nidorf SM; Thompson PL; Budgeon C; Tijssen JGP; Cornel JH
Eur Heart J; 2021 Jul; 42(28):2765-2775. PubMed ID: 33769515
[TBL] [Abstract][Full Text] [Related]
15. Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries.
Farnier M; Santos RD; Cosin-Sales J; Ezhov MV; Liu J; Granados D; Santoni S; Khan I; Catapano AL
Eur J Prev Cardiol; 2022 Dec; 29(17):2264-2271. PubMed ID: 36134461
[TBL] [Abstract][Full Text] [Related]
16. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis.
Kim KA; Kim NJ; Choo EH
Eur J Prev Cardiol; 2024 Feb; 31(3):291-301. PubMed ID: 37855457
[TBL] [Abstract][Full Text] [Related]
17. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
18. ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.
Sulman D; Zeitouni M; Silvain J; Kerneis M; Guedeney P; Barthélémy O; Brugier D; Sabouret P; Lattuca B; Mertens E; Posson J; Procopi N; Salloum T; Collet JP; Montalescot G
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):633-643. PubMed ID: 35381063
[TBL] [Abstract][Full Text] [Related]
19. CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL-Cholesterol to ACC/AHA and ESC/EAS Targets.
Mortensen MB; Steffensen FH; Bøtker HE; Jensen JM; Rønnow Sand NP; Kragholm KH; Kanstrup H; Sørensen HT; Leipsic J; Blaha MJ; Nørgaard BL
JACC Cardiovasc Imaging; 2020 Sep; 13(9):1961-1972. PubMed ID: 32563656
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
